Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Completed · Phase 2

Conditions studied: Alzheimer's Disease

In brief

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Key facts

Study ID

NCT00051909

Run by

Eli Lilly and Company

People needed

200

Starts

2002-11-01

Expected to finish

2003-06-01

Last updated by the study team

2006-07-19

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must have a clinical diagnosis of Alzheimer's Disease
• Must be at least 50 years of age
• Must fluently read and speak English
• Must have a reliable caregiver

You may not qualify if…

• Has serious health problems other than Alzheimer's Disease
• Cannot swallow whole pills
• Has had a menstrual period in the last two years
• Takes insulin for diabetes
• Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Where it is running

• Study site — Beverly Hills, California, United States
• Study site — Fresno, California, United States
• Study site — Boca Raton, Florida, United States
• Study site — Fort Lauderdale, Florida, United States
• Study site — Miami Beach, Florida, United States
• Study site — Boston, Massachusetts, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Tulsa, Oklahoma, United States
• Study site — Wichita Falls, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.